Repligen Co. (NASDAQ:RGEN) Stake Lifted by Tower Research Capital LLC TRC

Posted by on Aug 19th, 2023

Tower Research Capital LLC TRC increased its stake in Repligen Co. (NASDAQ:RGEN – Free Report) by 80.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,380 shares of the biotechnology company’s stock after acquiring an additional 1,959 shares during the period. Tower Research Capital LLC TRC’s holdings in Repligen were worth $737,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Lmcg Investments LLC boosted its holdings in shares of Repligen by 2.4% in the first quarter. Lmcg Investments LLC now owns 2,901 shares of the biotechnology company’s stock valued at $488,000 after acquiring an additional 67 shares in the last quarter. Securian Asset Management Inc. lifted its stake in Repligen by 2.1% during the fourth quarter. Securian Asset Management Inc. now owns 4,800 shares of the biotechnology company’s stock valued at $813,000 after purchasing an additional 100 shares during the last quarter. Lazard Asset Management LLC lifted its stake in Repligen by 15.4% during the fourth quarter. Lazard Asset Management LLC now owns 766 shares of the biotechnology company’s stock valued at $129,000 after purchasing an additional 102 shares during the last quarter. Cerity Partners LLC lifted its stake in Repligen by 6.3% during the fourth quarter. Cerity Partners LLC now owns 1,829 shares of the biotechnology company’s stock valued at $310,000 after purchasing an additional 109 shares during the last quarter. Finally, Whittier Trust Co. lifted its stake in Repligen by 108.6% during the first quarter. Whittier Trust Co. now owns 242 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 126 shares during the last quarter. 96.28% of the stock is currently owned by institutional investors.

Repligen Stock Down 3.1 %

Shares of RGEN opened at $157.80 on Friday. The company’s fifty day moving average is $158.95 and its 200-day moving average is $166.55. Repligen Co. has a 12 month low of $134.64 and a 12 month high of $241.82. The firm has a market cap of $8.80 billion, a price-to-earnings ratio of 65.21, a price-to-earnings-growth ratio of 3.71 and a beta of 1.01.

Repligen (NASDAQ:RGEN – Get Free Report) last posted its earnings results on Wednesday, August 2nd. The biotechnology company reported $0.53 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.49 by $0.04. Repligen had a net margin of 18.92% and a return on equity of 7.83%. The business had revenue of $159.20 million for the quarter, compared to analyst estimates of $165.93 million. During the same period last year, the business posted $0.91 EPS. Repligen’s revenue was down 23.3% compared to the same quarter last year. As a group, research analysts predict that Repligen Co. will post 1.83 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently commented on RGEN shares. Stephens upped their price target on shares of Repligen from $180.00 to $200.00 and gave the company an “overweight” rating in a research report on Thursday, August 3rd. StockNews.com started coverage on shares of Repligen in a research report on Thursday. They issued a “sell” rating for the company. Stifel Nicolaus reduced their price target on shares of Repligen from $210.00 to $200.00 in a research report on Wednesday, June 28th. Wells Fargo & Company assumed coverage on shares of Repligen in a research report on Thursday, July 20th. They issued an “overweight” rating and a $185.00 target price for the company. Finally, Deutsche Bank Aktiengesellschaft cut their target price on shares of Repligen from $180.00 to $165.00 in a research report on Wednesday, May 3rd. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, Repligen presently has a consensus rating of “Moderate Buy” and an average target price of $199.44.

Get Our Latest Stock Analysis on RGEN

About Repligen

(Free Report)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Read More

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN – Free Report).

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.